Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

September 17, 2026

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Performance

52-Week Range 15.1% below 52-week high

26.09

12.0052W Low 30.7452W High

1 Week 15.1% below 1-week high

25.861W Low 30.741W High

Adaptive Biotechnologies Corporation - Common Stock (ADPT) traded between $12.00 and $30.74 over the past 52 weeks and last traded at $26.09, 15.1% below its 52-week high. Over the past week it ranged between $25.86 and $30.74.

Past 12 Months

-4.7%

+7.2%

+29.4%

+75.8%

+64.0%

+81.8%

1W -$1.28

1M +$1.75

3M +$5.93

6M +$11.25

YTD +$10.18

1Y +$11.74

ADPT was +81.8% over the past year, +75.8% over six months, +64.0% year to date, -4.7% in the last week.

12 Months vs Market

ADPT

+81.8%

DIA

+9.8%

SPY

+15.7%

QQQ

+23.7%

IWM

+13.7%

Over the past 12 months ADPT returned +81.8% versus DIA (Dow) +9.8%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 1.11× 3-mo avg

Today 2,646,916 3-mo avg 2.4M

2.7M

2.5M

2.4M

2.5M

YTD

2.3M

ADPT most recently traded 2,646,916 shares against a 3-month average daily volume of 2.4M.

More News

September 01, 2026

Adaptive Biotechnologies Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗

July 29, 2026

Via Chartmill

Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

July 29, 2026

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗

July 12, 2026

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

July 09, 2026

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

June 17, 2026

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

June 15, 2026

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

June 15, 2026

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗

June 14, 2026

Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗

June 03, 2026

Via MarketBeat

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

May 29, 2026

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗

May 26, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

May 21, 2026

Adaptive (ADPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

May 05, 2026

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗

May 04, 2026

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗

April 20, 2026

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗

April 18, 2026

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

April 15, 2026

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗

April 08, 2026